QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and ... ( MELBOURNE Florida February 7 /- Q...)

QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp

Date:2/7/2008

MELBOURNE, Florida, February 7 /PRNewswire/ -- QuoNova LLC, which is 88.7% owned by XL TechGroup, Inc. (AIM: XLT), has generated preliminary in-vitro data indicating high efficacy of selected Quorum Sensing Blockers ("QSB") in inhibiting biofilm formation by MRSA (methicillin-resistant Staphylococcus aureus) strains and fungal organisms such as Candida sp.

QuoNova's business strategy is to develop and commercialize its proprietary QSB "disruptive technology" platform to address unmet needs in several multi-billion dollar markets including therapeutics, medical devices, consumer care, agriculture and several industrial applications.

QuoNova has optimized its proprietary QSB technology to obtain small molecules with a broad activity profile that are effective against multiple pathogenic Gram-positive and Gram-negative bacterial strains as well as fungi. These promising results, which are the subject of continuing research, further underscore the potential of QuoNova's QSB in combating the detrimental effects of biofilms, especially in clinical environments, where mixed microbial communities predominate. MRSA bacteria (hospital and community acquired) cause increasing healthcare problems due to their resistance against most conventional antibiotic therapies.

Importantly, QuoNova's QSB technology is an anti-virulence approach, which shows potential to prevent the consequences of infection from such drug-resistant bacteria, without inducing resistance itself. QuoNova recently demonstrated the efficacy of its QSB technology in a predictive animal model where QSBs significantly reduced the ability of clinically relevant bacteria to colonize secondary burn wounds. In addition, a marked synergy with Silver Sulfadiazine (SSD), a commonly used antibacterial preparation, was observed.

"These are promising results which significantly broaden the reach of our platform and further illustrate the impact of QuoNova's QSB technology in combating the
'/>"/>

1

GOOD

Page: 1 2 3 4
Related biology technology :

1. Egenix Licenses Harvard Anti-Cancer Platform
2. Nikon Instruments New NIS-Elements C Delivers Comprehensive Confocal and Widefield Imaging Capabilities in Single Unifying Software Platform
3. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
4. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
5. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
6. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
7. H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products
8. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
9. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
10. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
11. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections

Post Your Comments:

QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and ...( MELBOURNE Florida February 7 /- Q...)